Clinical and immunological results from phase 1/2 study of ino-3107 as a treatment for recurrent respiratory papillomatosis published in nature communications

Data shows that ino-3107 induced new populations of t cells in the blood that traveled to airway tissue and were associated with clinical benefit as measured by reduced need for surgeries plymouth meeting, pa. , feb. 12, 2025 /prnewswire/ -- inovio (nasdaq: ino), a biotechnology company focused on developing and commercializing dna medicines to help treat and protect people from hpv-related diseases, cancer, and infectious diseases, today announced that peer-reviewed data from its phase 1/2 clinical trial with ino-3107 as a potential treatment for recurrent respiratory papillomatosis (rrp) were published online in nature communications under the title dna immunotherapy for recurrent respiratory papillomatosis (rrp): phase 1/2 study assessing efficacy, safety, and immunogenicity of ino-3107.
INO Ratings Summary
INO Quant Ranking